Biotech

All Articles

Lilly posts a lot more good data on its own regular blood insulin possibility

.On the heels of an FDA rejection for its own chief competing Novo Nordisk, Eli Lilly is actually pu...

IN 8bio stops stage 2 trial, lays off one-half of workforce

.Just a handful of months after application the very first individual in a period 2 test for freshly...

Lilly, Haya ink $1B biobuck weight problems treaty to explore darker genome

.Eli Lilly's hunt for excessive weight intendeds has actually led it to the darker genome. The Big P...

ArsenalBio increases $325M, turns away from previous lead possession

.Toolbox Biosciences is actually carrying on up. The cell therapy provider has added $325 million in...

Lilly- backed effective weight loss biotech documents IPO

.After increasing $170 million back in February, metabolic disease-focused BioAge Labs has actually ...

Aelis' marijuana usage medicine fails period 2b, driving Indivior to reassess $100M possibility

.Aelis Farma's hopes of safeguarding an easy, favorable choice on a $one hundred million choice sett...

ProKidney halts phase 3 trial certainly not needed for tissue treatment confirmation

.ProKidney has actually ceased one of a set of stage 3 trials for its cell therapy for renal ailment...

Vaxcyte climbs on 'remarkable' 31-valent PCV succeed against Pfizer

.Vaxcyte revealed what professionals referred to as "remarkable" period 1/2 information for its own ...

Recursion's brain illness test presents scant evidence of efficacy

.Recursion has discovered via a very early exam of its tech-enabled strategy to medication discovery...

Acepodia, Pfizer click on with each other for chemistry-based tissue therapy

.Phone it an instance of good chemical make up: Acepodia, a biotech based on Nobel Champion scientif...